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Abstract: The aims of the present study were to evaluate the prevalence of undiagnosed mental
health conditions (UMHC) in people living with HIV (PLWHIV) on antiretroviral treatment and
with long-term suppressed HIV viremia, and its association with neurocognitive impairment (NCI).
A cross-sectional observational study on HIV subjects, ≥18 years old, on stable antiretroviral treatment
and with HIV viral load <50 copies/mL was carried out. Patients with known comorbidities, substances
abuse, anxiety or depression were excluded. UMHC were evaluated by the Millon Clinical Multiaxial
Inventory-III and NCI by Frascati criteria. The association between NCI and sociodemographic,
clinical HIV variables and mental health conditions was analyzed. Further, the relationship between
mental health conditions scores and NCI diagnosis was evaluated. Eighty patients were included,
37.5% had at least one undiagnosed mental health condition, and 26.3% had NCI. The most frequent
mental health conditions were: anxiety (21.3%); bipolar disorder (11.3%); and substance dependence
(8.8%). Only longer time since HIV diagnosis (p = 0.030) and at least one mental health condition
diagnosis (p = 0.002) showed an association with NCI. Participants with NCI presented higher scores
in anxiety, alcohol dependence and post-traumatic stress. Undiagnosed mental health conditions
are frequent in PLWHIV. These disorders cannot be identified by HIV clinicians or basic screening
questionnaires, and they are not usually self-reported by patients. UMHC could act as confounders
in the evaluation of NCI.
Keywords: mental health conditions; neurocognitive impairment; HIV infection; HIV-suppressed
viremia; behavior disorders
1. Introduction
Neurocognitive impairment (NCI) without an alternative explanation than HIV infection has
been described in people living with HIV (PLWHIV) [1]. Diagnosis of NCI in PLWHIV is based on
standardized neuropsychological tests and the exclusion of health problems [2]. Based on established
criteria and the severity of symptoms, NCI is categorized as asymptomatic neurocognitive impairment
(ANI), minor neurocognitive disorder (MND) or HIV-associated dementia [2]. This non-AIDS event has
severe negative consequences, such as poor adherence to antiretroviral therapy (ART) [3], difficulties
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in performing activities of daily living [4], loss of employment [5], a reduction in quality of life [6] and
higher mortality risk [7], among others.
There is no consensus about the prevalence of NCI in PLWHIV [8–15]. These discrepancies between
studies could be related to several factors. In this regard, the most important variables identified in the
previous research are based on the heterogeneous population included in the studies, differences in
HIV infection control or the lack of the identification of several comorbidities, something that could
increase the prevalence of NCI, such as mental health conditions [10,12,13].
Mental health conditions are more common in PLWHIV (63%) as compared to the HIV-negative
population (30.5%) [16]. Hence, when compared to their HIV-negative same sex counterparts,
HIV-positive men were more likely to have any mood disorder (odds ratio (OR) = 6.10), major depressive
disorder/dysthymia (OR = 3.77), any anxiety disorder (OR = 4.02) and any personality disorder
(OR = 2.50) [17]. The mechanisms underlying this higher prevalence in PLWHIV could be related
to the high exposition of this population to multiple stressful situations, such as stigmatization [18],
decreased social support and concerns after the HIV diagnosis [19].
Although both NCI and mental health conditions are highly prevalent in this population,
their bidirectional influence remains unclear, although it can influence the diagnosis of both.
International guidelines that have specific sections regarding diagnosis of HIV-associated NCI
recommend a complete assessment including a comprehensive clinical history and examination,
screening for depression, neuropsychological testing, cerebral MRI scanning and lumbar puncture [20].
For instance, European AIDS Clinical Society (EACS) guidelines recommend to exclude severe
psychiatric conditions, abuse of psychotropic drugs, alcohol abuse and depression, in order to confirm
that NCI is caused directly by HIV infection and not by a cofounder factor [21]. Despite these
recommendations, most of studies on NCI prevalence usually evaluate only depression and
anxiety [14,22], insomnia [23] or alcohol abuse [24]. The majority of studies do not evaluate and
identify the presence of other mental health conditions that could also have an influence on cognitive
performance [25]. Moreover, most of these studies evaluate only depression and anxiety through
the employment of screening scales or questionnaires, originally designed for the identification of
symptomatology and not mental health conditions [23,25]. Moreover, some studies do not follow these
recommendations and do not evaluate any mental health condition in this regard [26,27].
Furthermore, other facts related to these issues are based on the employment of screening tools
for mental health conditions which present some limitations, fundamentally, the lack of an exhaustive
and wide-range evaluation of mental health conditions beyond anxiety and depression symptoms [28].
This could explain why some studies find a relationship between mental health conditions and NCI [29],
while others do not [30].
As has been previously reported, mental health conditions and NCI can coexist in PLWHIV [31].
The Mind Exchange Working Group has reported that mental health conditions in HIV people can
act as a cofounder in NCI diagnosis [32]. For that reason, authors recommend to evaluate alcohol or
drug dependence, depression, anxiety and post-traumatic stress disorder, among others, before NCI
diagnosis [32]. Therefore, the lack of an exhaustive evaluation of mental health conditions in PLWIH,
with accurate and adequate evaluation instruments, could be on the basis of the discrepancies in
the influence of mental health conditions on NCI. In this regard, these controversial results make it
necessary to carry out new studies in this population to clarify this relationship, emphasizing the
necessity of employing previously validated diagnostic tests, with adequate psychometric properties,
for the evaluation of mental health conditions in-depth.
In a previous study of our group, the prevalence of NCI in “healthy” PLWHIV, with good
adherence to ART and long-term suppressed viremia and without medical or psychiatric comorbidities,
illegal drugs or alcohol abuse or psychotropic drugs users, was analyzed. The presence of depression
or anxiety was identified by the Hospital Anxiety and Depression Scale (HADS) questionnaire in all
patients. It was observed an NCI prevalence of 29.8% (95% CI: 21.0–40.2). Time since HIV diagnosis
and increasing levels of interleukin-6 were the only factors associated with NCI diagnosis [11]. Going
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one step further, the aims of the present study were to evaluate the prevalence of undiagnosed mental
health conditions (UMHC) in the same population and to analyze the possible association between
mental health conditions and NCI diagnosis.
2. Materials and Methods
2.1. Study Design and Participants
The study is a cross-sectional observational study. The sample of the present study was composed
of 80 PLWHIV. The inclusion criteria to participate in the study were: HIV infection, ≥18 years-old,
unchanged ART for at least one year, HIV-VL <50 copies/mL over the previous 12 months and completed
HADS [33] questionnaire with a score less than 10 points. The exclusion criteria were: self-reported poor
adherence to ART (<95% of antiretroviral drugs doses during previous month), smoking or substance
abuse (alcohol, methadone, psychotropic and recreational drugs) self-reported by patients or described
in the electronic medical reports during last 12 months, traumatic brain injury in the last 12 months
and presence of comorbidities identified in medical records: dementia or other central nervous
system diseases, mental health conditions diagnostic, viral chronic hepatitis, active cancer or infection,
diabetes mellitus, high blood pressure, cardiovascular disease, hypothyroidism or malnutrition. Finally,
mental or physical impairment that could hinder participants’ ability to complete or understand the
study questionnaires.
2.2. Variables
Sociodemographic and clinical HIV variables. Demographic variables were sex, age and education
level. HIV-related variables included HIV transmission mechanism, time since HIV diagnosis, current
and nadir CD4+ lymphocyte count.
Neurocognitive disorder (NCI). Frascati criteria were used for the diagnosis of neurocognitive
impairment. Based on the results of the neurocognitive evaluation, patients were classified as ANI,
MND or HIV-associated dementia [2]. ANI was defined by scores below 1.0 standard deviation (SD)
on the demographically corrected mean at least in 2 neuropsychological domains with no interference
in daily functioning. MND was categorized with same scores of ANI but in this case with interference
in daily functioning. HIV-associated dementia was defined by at least two domains with a score of
≥2 SDs below the mean, with significant interference in daily function.
To asses interference in daily life, patients were asked if cognitive impairment interfered or not,
at least mildly, in one of the following areas: work, household, mental acuity, tasks or social activities [2].
This variable was expressed as a dichotomous categorical variable (yes/no).
Mental health conditions. For the assessment of mental health conditions, the Spanish version
of the Millon Clinical Multiaxial Inventory-III (MCMI-III) was employed [34,35]. This is a 175-item
self-report scale with two response options (true or false) that assesses 14 personality disorders
and 10 clinical syndromes. For the present study, only mental health conditions were evaluated:
anxiety disorder, somatoform disorder, bipolar disorder, dysthymic disorder, alcohol dependence,
substance dependence, post-traumatic stress, thought disorder, major depression and delusional
disorder. The MCMI-III was corrected online on the platform of Pearson Clinical & Talent Assessment,
Q-global. MCMI-III has good psychometric properties, with a test–retest reliability between 0.84 and
0.96 and an internal consistency higher than 0.80. Regarding the internal consistency of each scale,
the validation of the questionnaire exhibited an adequate reliability index, exceeding in more than
21 scales the value of the coefficients alpha 0.75. Results are expressed according to the MCMI-III
criteria, where raw scores are transformed into prevalence scores. Following the authors’ instructions,
a score >75 points was employed as a cut-off score in each item to define the presence of mental health
conditions, being classified as “presence” or “absence”. Finally, patients were categorized as having
“at least one mental health conditions” or not [35].
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Procedure
In the first meeting, after informed consent was signed by participants, a clinician and a
neuropsychologist reviewed all electronic clinical reports shared with psychiatrists and family doctors
and performed a structured clinical interview to ensure the fidelity of inclusion/exclusion criteria prior
to the administration of neuropsychological tests. Further, participants self-completed an anxiety and
depression screening questionnaire (HADS) [33]. If participants scored 10 or more, they were excluded
from participation in the study. The sociodemographic and clinical variables were collected from the
medical records.
In the second visit, a trained neuropsychologist conducted a personal interview with each
participant, lasting approximately 120 min and consisting of an administration of a comprehensive
neurocognitive battery that covers seven neurocognitive domains (ND), following the established
criteria by international consensus [2]. This battery was composed by the following two tests to evaluate
each ND: speed of information processing (Trail making Test Form A and WAIS-IV Digit Symbol);
verbal fluency (PMR and animals); attention/working memory (WAIS-IV Digit Span and D2, Test of
Attention); executive function (Trail making Test Form A, Five Digit Test and The Towel of London
Test); motor function (Grooved Pegboard Test and The MacQuarrie Test); learning (TAVEC—Consistent
Long-Term Retrieval and Brief Visuospatial Memory Test-Revised-Total Learning) and delayed recall
(TAVEC-delayed recall and Brief Visuospatial Memory Test-delayed recall). Spanish versions of all the
tests were used. Z-scores were obtained of raw corrected by age, education level and sex from Spanish
normative data. The neuropsychology battery was administered always by the same neuropsychologist.
In a third visit, the same neuropsychologist conducted a personal interview with each participant,
lasting approximately 30 min and consisting of an administration of the Millon Clinical Multiaxial
Inventory-III (MCMI-III) [35].
The study was carried out in the Infectious Diseases Unit of the General University Hospital of
Alicante in Spain, which attends approximately 1250 PLWHIV. All patients in usual care between
November 2014 and February 2015 who met the inclusion criteria were invited to participate in the
study. Only 8 patients, who complied with the inclusion criteria, refused to participate in the study,
primarily due to a lack of time to perform the neuropsychological tests. Four patients were also
excluded because they did not complete properly the Millon Clinical Multiaxial Inventory-III.
The study was approved (26 November 2014) by the Ethics Committee of the General University
Hospital of Alicante (PI2013/25). The project was carried out in accordance with good clinical practice
standards and international ethical principles applicable to medical research in humans. All participants
provided written informed consent.
2.3. Data Analysis
To describe the population in qualitative variables, absolute frequencies and percentages were
used. With regard to quantitative variables, the Kolmogorov–Smirnov test was employed to determine
the normality of the data distribution. Further, quantitative variables were dichotomized using clinical
criteria (time since HIV diagnosis) or variable distribution (age). The prevalence of NCI and mental
health conditions was calculated with a 95% confidence interval (CI). Chi-squared test was employed
to assess associations between NCI sociodemographic, clinical HIV variables and mental health
conditions. Further, the crude odds ratio (OR) and 95% CI were calculated. Variables which showed
a significant (p < 0.05) association in bivariate analysis were fitted in a logistic regression model to
calculate the adjusted OR. Moreover, each mental health conditions was analyzed as a continuous
variable to study the relationship between their scores and the NCI diagnosis by the student´s t-test
or Mann–Whitney U test as appropriate. The level of statistical significance in the hypothesis testing
was p < 0.05. For data analysis, the software package IBM-SPSS Statistics 25.0 (Armonk, NY, USA)
was used.
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3. Results
3.1. Sociodemographic and Clinical Characteristics of the Sample
Eighty patients were included, 77.5% were males with a mean age of 46.1 ± 7.6 years, and 66.3%
had secondary or university studies. Concerning clinical variables, the mean of time since diagnosis
was 12.4 ± 7.1 years (Table 1).
Table 1. Descriptive analysis of people living with HIV (PLWHIV) included in the study (N = 80).
Sociodemographic and Clinical Characteristics Variables
Male, n (%) 77.5 (62)
Age (years), mean ± SD 46.1 ± 7.6
Age (≥44 years), n (%) 56.3 (45)
Educational levels, n (%):
Primary or no education 33.8 (27)
Secondary education 41.3 (33)
University education 25.0 (20)
Clinical HIV variables
HIV transmission mechanism, n (%)
Former-IDU 1 7.5 (6)
Sexual: 92.4 (74)
MSM 2 58.8 (47)
HTX 3 33.8 (27)
Time since HIV diagnosis (years), mean ± SD 12.4 ± 7.1
≥10 years since HIV diagnosis, n (%) 61.3 (49)
Current CD4+ lymphocytes (cells/µL.), mean ± SD 653.5 ± 219.5
Current CD4+ count < 500 cells/µL., n (%) 23.8 (19)
Nadir CD4+ lymphocyte (cells/µL.), mean ± SD 246.0 ± 151.6
Nadir CD4+ count ≤ 350 cells/µL, n (%) 76.3 (61)
1 Previous intravenous drug users; 2 men who have sex with men; 3 heterosexual.
3.2. Prevalence of NCI and Mental Health Conditions
The NCI prevalence observed was 26.3% (16.1–36.5). Using Frascati criteria, patients were
categorized as ANI: 13 (16.3%); MNI: 7 (8.8%); and HIV-associated dementia: 1 (1.3%) patients.
Table 2 shows the prevalence of mental health conditions in the study population. The most
frequent disorders were: anxiety (21.3%); bipolar (11.3%); and substance dependence (8.8%). A total of
37.5% (26.3–48.7%) of the patients evaluated had at least one mental health condition.
Table 2. Prevalence of mental health conditions according to the Millon Clinical Multiaxial Inventory-III
(N = 80).
Mental Health Conditions Prevalence (95% CI) 1 n
Anxiety 21.3 (11.7–30.8) 17
Somatoform 5.0 (1.4–12.3) 4
Bipolar 11.3 (3.7–18.8) 9
Dysthymia 2.5 (0.3–8.7) 2
Alcohol dependence 2.5 (0.3–8.7) 2
Drug dependence 8.8 (1.9–15.6) 7
Post-traumatic stress - 0
Thought disorder 5.0 (1.4–12.3) 4
Major depression - 0
Delusional disorder 6.3 (2.0–14.0) 5
At least one mental health
condition 37.5 (26.3–48.7) 30
1 Confidence interval 95%.
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3.3. Association between Sociodemographic, Clinical-HIV Variables and Mental Health Conditions with
NCI Diagnosis
In the multivariate analysis, only time since HIV diagnosis and at least one UMHC showed a
significant association with NCI diagnosis (Table 3).
Table 3. Association between sociodemographic, clinical HIV variables and mental health conditions
with neurocognitive impairment (NCI) diagnosis (N = 80).
Sociodemographic, Clinical












Male 22.6 (14/62) 0.5 (0.2–1.5) 0.224 - -
Female 38.9 (7/18) 1
Age
≥44 years 31.1 (14/45) 1.8 (0.6–5.1) 0.263 - -
<44 years 20.0 (7/35) 1
Education level
Non/Primary 37.0 (10/27) 2.7 (1.0–7.0) 0.118 - -
Secondary/University 20.8 (11/53) 1
HIV mechanism transmission
Former-IDU 1 33.3 (2/6) 1.5 (0.3–8.6) 0.650 - -
Sexual 2 25.7 (21/80) 1
Time since diagnosis
≥10 years 36.7 (18/49) 5.5 (1.4–20.4) 0.007 5.0(1.2–21.6) 0.030
<10 years 9.7 (3/31) 1
Current CD4+ (cells/µL)
<500/µL 21.1 (4/19) 0.7 (0.2–2.4) 0.767 - -
≥500/µL 27.9 (17/61) 1
Nadir CD4+ (cells/µL)
≤350/µL 32.8 (20/61) 8.8 (1.1–70.5) 0.018 6.6(0.7–59.4) 0.095
>350/µL 5.3 (1/19) 1
At least one mental health condition
Presence 46.7 (14/30) 5.4 (1.8–15.7) 0.001 6.3(1.9–20.8) 0.002
Absence 14.0 (7/50) 1
1 Previous intravenous drug users; 2 sexual transmission; 3 crude odds ratio; 4 confidence interval 95%; 5 crude
statistical significance; 6 adjusted odds ratio; 7 adjusted statistical significance.
3.4. Relation of Mental Health Conditions Score and NCI
Regarding differences in the score of each mental health conditions depending on NCI diagnosis,
observed were significant differences in anxiety (p = 0.028), alcohol dependence (p = 0.029) and
post-traumatic stress (p = 0.039). For all cases, PLWHIV with NCI diagnosis showed higher levels of
symptoms of these mental health conditions in comparison to their counterparts without NCI diagnosis
(Table 4).
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Table 4. Results of comparing the means for NCI or not samples in mental health conditions (N = 80).
Mental Health Conditions
Neurocognitive Impairment





M 1 SD 2 M 1 SD 2
Anxiety 50.9 32.6 33.1 30.8 2.2 0.028 0.56
Somatoform 34.8 27.7 27.4 26.5 1.1 0.285 0.28
Bipolar 54.5 22.9 43.4 24.4 1.8 0.072 0.47
Dysthymia 31.2 25.3 20.4 24.1 1.8 0.085 0.44
Alcohol dependence 44.6 25.3 31.4 22.8 2.2 0.029 0.55
Drug dependence 41.0 27.9 32.9 25.2 1.2 0.222 0.30
Post-traumatic stress 32.3 22.2 20.2 22.9 2.1 0.039 0.53
Thought disorder 34.3 28.7 26.4 24.6 1.2 0.229 0.30
Major depression 25.7 28.6 21.7 23.0 0.6 0.569 0.15
Delusional disorder 37.2 34.5 33.1 31.6 0.5 0.618 0.12
1 Media; 2 standard deviation; 3 t-test for comparing two means; 4 p: statistical significance; 5 d: Cohen’s d.
4. Discussion
Based on the results obtained in this study, it would be necessary to establish specific protocols to
diagnose mental health conditions in PLWHIV. We propose that an exhaustive mental health conditions
evaluation through a previously validated questionnaire, such as the Millon Clinical Multiaxial
Inventory-III, should be performed, at least once a year, in PLWHIV followed up in HIV infection
units. Further, this exhaustive evaluation should be always done before an NCI evaluation. In case of
a positive result, the patient should be referred to a mental health unit.
Results of the present study show a high prevalence of UMHC in PLWHIV without comorbidities
with good adherence to ART and long-term suppressed viremia. This prevalence was found even
though there was previous exclusion of those participants with known mental health conditions after
reviewing electronic clinical records and performing the HADS questionnaire to discard anxiety or
depression symptoms in “healthy” PLWHIV. Surprisingly, after the evaluation with the MCMI-III
questionnaire, it was found a high proportion of mental health conditions in the analyzed sample,
including depression, anxiety, bipolar and substance abuse, among others, non-previously identified
through the employment of classical used screening questionnaires, such as HADS. Although substance
abuse was an exclusion criterion, no previously self-reported drugs and alcohol dependence was
identified in 8.8% and 2.5% of patients, respectively. In summary, 37.5% of the patients presented at
least one mental health condition, being anxiety and bipolar disorders the most prevalent.
As it has been reported previously, the prevalence of NCI is high (26.3%) in the studied
population [11]. In the multivariate analysis, more than ten years since HIV diagnosis (ORa 5.0
(1.2–21.6)) and having at least one mental health condition (ORa 6.3 (1.9–20.8)) were associated with
NCI diagnosis. Higher scores in anxiety, alcohol dependence and post-traumatic stress mean were
observed in patients with NCI diagnosis.
The results of this research are in accordance with previous literature, in which it has been
demonstrated that there is a high prevalence of mental health conditions in different HIV populations.
Patients with HIV infection can live traumatic life events [36], are exposed to side effects of
antiretroviral drugs and suffer non-AIDS comorbidities which can influence on health behaviors [37].
Major depression, dysthymia and anxiety disorders are frequent in PLWHIV and more prevalent in
comparison to the general population without HIV infection when groups are matched by age and
sex [17]. UMHC could have severe negative consequences, for instance, depression has been associated
to less adherence to ART resulting in virological failure, decline in lymphocyte CD4+ recount [38],
resistance to antiretroviral drugs and increase in mortality [39,40]. Other authors have associated
Diagnostics 2020, 10, 543 8 of 12
depression with risky sexual practices for HIV transmission, such as promiscuity, anonymous sex and
sex relations without the use of condoms [41,42].
A higher percentage of HIV people report abuse of toxic substances and illegal drugs compared
with the general population [43]. Chronic alcohol consumption is associated to lower adherence to
ART [44], caloric-protein malnutrition, immunosuppression, virological failure [45], chronic liver
disease [46] and alteration of antiretroviral drugs metabolism [47]. In this research, we observed a
minor proportion of patients who are dependent on addictive substances, something that was unknown
to HIV clinicians and was not self-reported previously by patients. Chemsex-related drug use is an
escalating public health issue among men who have sex with men, associated with significant physical,
biomedical and psychosocial harm [48]. Generally, Chemsex is not self-reported by the patients to HIV
clinicians and it is not identified as drug abuse by patients themselves. Long-term outcome of HIV
patients with undiagnosed substance abuse is unknown.
Although we excluded patients with symptomatology of anxiety and depression using the
HADS questionnaire and reviewing clinical records, our results show that there are still UMHC not
identified by these evaluation strategies which could influence in the diagnosis of NCI. Based on
previous research, there is some controversy in this regard. Fialho explored the relationship between
depressive symptoms and neuropsychological performance in women living with HIV, some of
them with bad adherence to ART and detectable HIV-VL. In the multivariate model, only depressive
symptoms were associated with NCI [29]. Further, the studies from the CHARTER group (CNS HIV
Antiretroviral Effects Research) and other groups have demonstrated an association between mental
health conditions and NCI [9,31,49,50]. However, Cysique affirms that depression and anxiety do not
affect NCI [30]. Authors of the PIVOT study [15] and others [23,27] describe factors associated with
NCI in PLWHIV on stable combination ART, a population quite similar to our study, not reporting
association between depression and NCI. In these studies, depression and anxiety were the only mental
health conditions analyzed, being evaluated by screening questionnaires specifically designed for the
identification of symptomatology, but not as mental health conditions properly [23,27]. Other mental
health conditions that have demonstrated to have a significant impact on cognitive functioning, such as
bipolar disorder [32,51], drug or alcohol abuse [32,52] or delusional disorder [53], among others,
were not evaluated in these studies. The poor assessment of mental health conditions and the use of
screening methods may be the cause of the lack of congruence in the literature on the relationship
between mental health conditions and NCI. The obtained results point out that probably screening
tests might not be adequate to discard mental health conditions in PLWHIV.
Based on all of this information mentioned above and with the aim to identify which specific
mental health conditions could be related to NCI diagnosis, differences between groups with or without
NCI diagnosis were conducted. As it has been described by other authors, higher scores in anxiety,
alcohol dependence and post-traumatic stress in PLWHIV with NCI diagnosis were, as in [24,32,54].
We highlight the high prevalence of NCI in well-controlled PLWHIV, without comorbidities
including mental health conditions. Therefore, pathogenic mechanisms such as HIV neurotropism or
chronic inflammation could play a main role in NCI development in this selected population [11].
Although the present study entails an advance in the comprehension of the association between
mental health conditions and NCI in PLWHIV, some limitations should be taken into account.
The design of the study only allows to measure the association of mental health conditions with NCI,
avoiding establishing any causality. Further, the inclusion and exclusion criteria used in our study
do not permit extrapolating the results to the whole population of PLWHIV. However, our study has
several methodological strengths compared to other studies and this allows us to draw significant
conclusions. In comparison to previous research, we recruited a population not enough studied
in neuropsychological research, that is to say, only well-controlled PLWHIV without comorbidities.
Secondly, we have done an exhaustive and comprehensive analysis of the main mental health conditions.
Moreover, to our knowledge, the Millon Clinical Multiaxial Inventory-III questionnaire has not been
previously employed to discard the effects of mental health conditions on NCI diagnosis in PLWHIV.
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5. Conclusions
In conclusion, our study highlights that UMHC are frequent in PLWHIV, even in well-controlled
HIV subjects. These disorders are not recognized by clinicians, not self-reported by patients or not
identified by basic screening questionnaires. Some of these UMHC could have serious implications in
public health, affect the control of HIV infection and even act as confounders of NCI diagnosis.
Basic screening instruments such as HADS are not enough to exclude mental health conditions
in PLWHIV. Other mental health conditions than anxiety and depression should be evaluated in this
population, for instance, in patients with bad ART adherence, frequent virologic failure or before NCI
diagnosis. These tests could avoid NCI over diagnosis and avoiding the added stress of a misdiagnosis.
Based on the results, it is necessary to carry out more neuropsychological studies in PLWHIV
given the vulnerability of this population using diagnostic questionnaires to evaluate mental health
conditions. Future studies should develop longitudinal studies in order to identify how mental health
conditions have an effect on NCI and how they could be detrimental to cognitive functioning, analyzing
their particular influence on several cognitive domains.
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